Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 3 1Phase 2 1

Status

Recruiting 4Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Other solid neoplasm 1

Conditions

Breast Neoplasms 3Polycystic Ovary Syndrome 1Pediatric Brain Tumor 1Hyperinsulinism 1

Interventions

Specimen Handling 613pembrolizumab 563Magnetic Resonance Spectroscopy 536Carboplatin 425Cisplatin 375Cyclophosphamide 373Biopsy 357Paclitaxel 306Gemcitabine 303Nivolumab 300Radiotherapy 260Bevacizumab 234Dexamethasone 209fludarabine 205Docetaxel 187durvalumab 182atezolizumab 173Oxaliplatin 172venetoclax 168Fluorouracil 166Rituximab 165Pemetrexed 163Capecitabine 158Doxorubicin 157Radiation 155Radiosurgery 148Etoposide 137Leucovorin 133Ipilimumab 133Lenalidomide 131

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × dapagliflozin × 90 days × Clear all
NCT06405178 2026-06-02

Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Beni-Suef University

Phase 3 Completed
200 enrolled

Polycystic Ovary Syndrome

NCT05989347 2026-05-22

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Yale University

Phase 1 Recruiting
20 enrolled
Breast

Breast Neoplasms, Hyperinsulinism

NCT07070765 2026-04-30

SPRINT

University of Aberdeen

Phase NA Recruiting
70 enrolled
Breast

Breast Neoplasms

NCT06427226 2026-04-17

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Tanta University

Phase 2 Recruiting
46 enrolled
Breast

Breast Neoplasms

NCT05521984 2026-04-02

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Washington University School of Medicine

Phase 1 Recruiting
20 enrolled
Other solid neoplasm

Pediatric Brain Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡